1-4 of 4
Matthew Wongchenko
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

Christopher J. Sweeney, Russell Petry, Chang Xu, Merrida Childress, Jie He, David Fabrizio, Ole Gjoerup, Samantha Morley, Timothy Catlett, Zoe J. Assaf, Kobe Yuen, Matthew Wongchenko, Kalpit Shah, Pratyush Gupta, Priti Hegde, Lincoln W. Pasquina, Sanjeev Mariathasan, Ryon P. Graf, Thomas Powles
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4115–4122.
https://doi.org/10.1158/1078-0432.CCR-24-1096
Published: 13 September 2024
View article titled, Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 46–53.
https://doi.org/10.1158/1078-0432.CCR-18-4180
Published: 03 January 2020
View article titled, Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <em>BRAF</em>-Mutant Melanoma
Open the PDF for Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Inês Pires da Silva, Kevin Y.X. Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John J. Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A. Scolyer, Jean Y.H. Yang, Georgina V. Long, Alexander M. Menzies
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1272–1279.
https://doi.org/10.1158/1078-0432.CCR-18-1680
Published: 15 February 2019
View article titled, Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma
Open the PDF for Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodríguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andrés Cervantes, Josep Tabernero, Premal Patel, José Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (24): 6976–6986.
https://doi.org/10.1158/1078-0432.CCR-13-0978
Published: 16 December 2013
View article titled, Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Open the PDF for Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068 in another window
Includes: Supplementary data